Evidence map›Paper›PMID 26035702›Full record

Trial reportBritish journal of cancer2015

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

C J Langer, V Hirsh, I Okamoto, F-J Lin, Y Wan, S Whiting, T J Ong, M F Renschler, M F Botteman

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00540514 (A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00540514 phase3completednot on this map

A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorCelgeneRan2007 to 2013Enrolled1,052ConditionsNon-Small Cell Lung CarcinomaArmsAlbumin-bound paclitaxel, Paclitaxel, Carboplatin
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Understanding Treatment Tolerability in Older Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

C J LangerAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
V HirshDepartment of Oncology, McGill University, Montreal, Quebec, Canada.
I OkamotoDepartment of Medical Oncology, Kinki University, Osaka-Sayama, Japan.
F-J LinPharmerit International, Bethesda, MD, USA.
Y WanPharmerit International, Bethesda, MD, USA.
S WhitingCelgene Corporation, Summit, NJ, USA.
T J OngCelgene Corporation, Summit, NJ, USA.
M F RenschlerCelgene Corporation, Summit, NJ, USA.
M F BottemanPharmerit International, Bethesda, MD, USA.
Pharmerit (United States) · USKindai University · JPMcGill University · CAUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients.

methodsUsing age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate (ORR), overall survival (OS), progression-free survival (PFS), quality of life (QoL), safety/toxicity, and quality-adjusted time without symptoms or toxicity (Q-TWiST) with ages ⩾60 and ⩾70 years as cut points.

resultsAmong patients aged ⩾60 years (N=546), nab-PC (N=265) significantly increased ORR and prolonged OS, despite a non-significant improvement in PFS, vs sb-PC (N=281). Nab-PC improved QoL and was associated with less neuropathy, arthralgia, and myalgia but resulted in more anaemia and thrombocytopenia. Nab-PC yielded significant Q-TWiST benefits (11.1 vs 9.8 months; 95% CI of gain: 0.2-2.6), with a relative Q-TWiST gain of 10.8% (ranging from 6.4% to 15.1% in threshold analysis). In the ⩾70 years age group, nab-PC showed similar, but non-significant, ORR, PFS, and Q-TWiST benefits and significantly improved OS and QoL.

conclusionNab-PC as first-line therapy in older patients with advanced NSCLC increased ORR, OS, and QoL and resulted in quality-adjusted survival gains compared with standard sb-PC.

Indexed as

Survival AnalysisAgedAged, 80 and overAlbumin-Bound PaclitaxelAlbuminsAntineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedPaclitaxelQuality of LifeTreatment OutcomeAlbumin-Bound PaclitaxelAlbuminsAntineoplastic Agents, PhytogenicPaclitaxel

Identifiers

PMID26035702
PMCPMC4647528
OpenAlexW1485401317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.